NCT01688037View on ClinicalTrials.gov

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions
Tardive Dyskinesia
Interventions
DRUG

NBI-98854

25 mg capsule

DRUG

NBI-98854

50 mg capsule

DRUG

Placebo

Trial Locations (51)

10035

Wards Island

11203

Brooklyn

12208

Albany

19428

Conshohocken

21061

Glen Burnie

21285

Baltimore

28348

Hope Mills

29407

Charleston

30342

Atlanta

32763

Orange City

32901

Melbourne

33012

Hialeah

33161

North Miami

33166

Miami Springs

33319

Lauderhill

33334

Fort Lauderdale

38119

Memphis

44122

Beachwood

60194

Schaumburg

60612

Chicago

60640

Chicago

63118

St Louis

63141

St Louis

70114

New Orleans

71104

Shreveport

72211

Little Rock

73112

Oklahoma City

75062

Irving

75115

DeSoto

90241

Downey

90723

Paramount

90746

Carson

91206

Glendale

91950

National City

92056

Oceanside

92103

San Diego

92108

San Diego

92121

San Diego

92123

San Diego

92324

Colton

92408

San Bernardino

92626

Costa Mesa

92705

Santa Ana

92708

Fountain Valley

92804

Anaheim

98011

Bothell

98033

Kirkland

99204

Spokane

08755

Toms River

00725

Caguas

00927

San Juan

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY